                         SEQUENCE LISTING

<110>  Beijing Mabworks Biotech Co., Ltd
 
<120> ANTIBODIES BINDING PD-L1 AND USES THEREOF

<130>  55556 00060

<150>  CN202110284404.8
<151>  2021-03-16

<160>  37    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1 of mouse, chimeric and humanized 3C2 antibodies

<400>  1

Asp Tyr His Val Asn 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2 of mouse, chimeric and humanized 3C2 antibodies

<400>  2

Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3 of mouse, chimeric and humanized 3C2 antibodies

<400>  3

Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr 
1               5                   10      


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1 of mouse, chimeric and humanized 3C2 antibodies

<400>  4

Lys Ala Ser Asp Arg Ile Asn Asn Trp Leu Ala 
1               5                   10      


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2 of mouse, chimeric and humanized 3C2 antibodies

<400>  5

Gly Ala Thr Ser Leu Glu Thr 
1               5           


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3 of mouse, chimeric and humanized 3C2 antibodies

<400>  6

Gln Gln Tyr Trp Asn Ile Pro Phe Thr 
1               5                   


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1 of mouse, chimeric and humanized 56E5 antibodies

<400>  7

Ser Asp Tyr Trp Asn 
1               5   


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2 of mouse, chimeric and humanized 56E5 antibodies

<400>  8

Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3 of mouse, chimeric and humanized 56E5 antibodies

<400>  9

Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr 
1               5                   10      


<210>  10
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1 of mouse, chimeric and humanized 56E5 antibodies

<400>  10

Lys Ser Ser Gln Ser Leu Leu Ile Ser Gly Asn Gln Lys Asn Phe Leu 
1               5                   10                  15      


Thr 
    


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2 of mouse, chimeric and humanized 56E5 antibodies

<400>  11

Trp Ala Ser Thr Arg Glu Ser 
1               5           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3 of mouse, chimeric and humanized 56E5 antibodies

<400>  12

Gln Asn Asp Phe Gly Phe Pro Phe Thr 
1               5                   


<210>  13
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of mouse and chimeric 3C2 antibodies

<400>  13

Gln Val Gln Leu Asn Gln Ser Gly Pro Glu Leu Met Lys Ala Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Leu Ser Phe Thr Thr Ala Tyr 
65                  70                  75                  80  


Ile Met Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  14
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanzed antibodies 3C2-VH2VL2, 3C2-VH2VL3, and 3C2-VH2VL4

<400>  14

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  15
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 3C2-VH3VL2, 3C2-VH3VL3, and 3C2-VH3VL4

<400>  15

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  16
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 3C2-VH4VL2, 3C2-VH4VL3, and 3C2-VH4VL4

<400>  16

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  17
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 3C2-VH5VL2, 3C2-VH5VL3, and 3C2-VH5VL4

<400>  17

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  18
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibody 3C2-VH6VL5

<400>  18

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


His Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Ser Gly Arg Thr Phe Tyr Thr Asp Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asp Tyr Gly Thr Ser Gly Tyr Gly Leu Val Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  19
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of mouse and chimeric 56E5 antibodies

<400>  19

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Ala Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Lys Phe Pro Gly Asn Lys Leu Glu Tyr Met 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Tyr Tyr Leu 
65                  70                  75                  80  


Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  20
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 56E5-VH2VL2, 56E5-VH2VL3, and 56E5-VH2VL4

<400>  20

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Thr Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Thr Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  21
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 56E5-VH3VL2, 56E5-VH3VL3 and 56E5-VH3VL4

<400>  21

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln His Pro Gly Asn Lys Leu Glu Tyr Met 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Thr Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Thr Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  22
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 56E5-VH4VL2, 56E5-VH4VL3 and 56E5-VH4VL4

<400>  22

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln His Pro Gly Asn Lys Leu Glu Tyr Met 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Thr Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  23
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of humanized antibodies 56E5-VH5VL2, 56E5-VH5VL3 and 56E5-VH5VL4

<400>  23

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln His Pro Gly Asn Lys Leu Glu Tyr Met 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Thr Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Arg Asp Trp Asp Val Arg Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  24
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of mouse and chimeric 3C2 antibodies

<400>  24

Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Arg Val Thr Ile Ser Cys Lys Ala Ser Asp Arg Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 
65                  70                  75                  80  


Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  25
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 3C2-VH2VL2, 3C2-VH3VL2, 3C2-VH4VL2 and 3C2-VH5VL2

<400>  25

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp Arg Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  26
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 3C2-VH2VL3, 3C2-VH3VL3, 3C2-VH4VL3 and 3C2-VH5VL3

<400>  26

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Lys Ala Ser Asp Arg Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  27
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 3C2-VH2VL4, 3C2-VH3VL4, 3C2-VH4VL4 and 3C2-VH5VL4

<400>  27

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Lys Ala Ser Asp Arg Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Val Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  28
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibody 3C2-VH6VL5

<400>  28

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp Arg Ile Asn Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  29
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of mouse and chimeric 56E5 antibodies

<400>  29

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Asn Cys Lys Ser Ser Gln Ser Leu Leu Ile Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Phe Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Phe Gly Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  30
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 56E5-VH2VL2, 56E5-VH3VL2, 56E5-VH4VL2 and 56E5-VH5VL2

<400>  30

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Met Asn Cys Lys Ser Ser Gln Ser Leu Leu Ile Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Phe Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Phe Gly Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  31
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 56E5-VH2VL3, 56E5-VH3VL3, 56E5-VH4VL3 and 56E5-VH5VL3

<400>  31

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Asn Cys Lys Ser Ser Gln Ser Leu Leu Ile Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Phe Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Phe Gly Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  32
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of humanized antibodies 56E5-VH2VL4, 56E5-VH3VL4, 56E5-VH4VL4 and 56E5-VH5VL4

<400>  32

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Asn Cys Lys Ser Ser Gln Ser Leu Leu Ile Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Phe Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Phe Gly Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  33
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IgG1 constant region (N297A)

<400>  33

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  34
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human kappa constant region

<400>  34

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  35
<211>  290
<212>  PRT
<213>  Homo sapiens

<400>  35

Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu 
1               5                   10                  15      


Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr 
            20                  25                  30          


Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu 
        35                  40                  45              


Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile 
    50                  55                  60                  


Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser 
65                  70                  75                  80  


Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn 
                85                  90                  95      


Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr 
            100                 105                 110         


Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val 
        115                 120                 125             


Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val 
    130                 135                 140                 


Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr 
145                 150                 155                 160 


Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser 
                165                 170                 175     


Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn 
            180                 185                 190         


Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr 
        195                 200                 205             


Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu 
    210                 215                 220                 


Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His 
225                 230                 235                 240 


Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr 
                245                 250                 255     


Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys 
            260                 265                 270         


Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu 
        275                 280                 285             


Glu Thr 
    290 


<210>  36
<211>  290
<212>  PRT
<213>  Macaca fascicularis

<400>  36

Met Arg Ile Phe Ala Val Phe Ile Phe Thr Ile Tyr Trp His Leu Leu 
1               5                   10                  15      


Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr 
            20                  25                  30          


Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu 
        35                  40                  45              


Asp Leu Thr Ser Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile 
    50                  55                  60                  


Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Asn 
65                  70                  75                  80  


Tyr Arg Gln Arg Ala Gln Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn 
                85                  90                  95      


Ala Ala Leu Arg Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr 
            100                 105                 110         


Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val 
        115                 120                 125             


Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val 
    130                 135                 140                 


Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr 
145                 150                 155                 160 


Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser 
                165                 170                 175     


Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Leu Asn 
            180                 185                 190         


Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Ala Asn Glu Ile Phe Tyr 
        195                 200                 205             


Cys Ile Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu 
    210                 215                 220                 


Val Ile Pro Glu Leu Pro Leu Ala Leu Pro Pro Asn Glu Arg Thr His 
225                 230                 235                 240 


Leu Val Ile Leu Gly Ala Ile Phe Leu Leu Leu Gly Val Ala Leu Thr 
                245                 250                 255     


Phe Ile Phe Tyr Leu Arg Lys Gly Arg Met Met Asp Met Lys Lys Cys 
            260                 265                 270         


Gly Ile Arg Val Thr Asn Ser Lys Lys Gln Arg Asp Thr Gln Leu Glu 
        275                 280                 285             


Glu Thr 
    290 


<210>  37
<211>  290
<212>  PRT
<213>  Mus musculus

<400>  37

Met Arg Ile Phe Ala Gly Ile Ile Phe Thr Ala Cys Cys His Leu Leu 
1               5                   10                  15      


Arg Ala Phe Thr Ile Thr Ala Pro Lys Asp Leu Tyr Val Val Glu Tyr 
            20                  25                  30          


Gly Ser Asn Val Thr Met Glu Cys Arg Phe Pro Val Glu Arg Glu Leu 
        35                  40                  45              


Asp Leu Leu Ala Leu Val Val Tyr Trp Glu Lys Glu Asp Glu Gln Val 
    50                  55                  60                  


Ile Gln Phe Val Ala Gly Glu Glu Asp Leu Lys Pro Gln His Ser Asn 
65                  70                  75                  80  


Phe Arg Gly Arg Ala Ser Leu Pro Lys Asp Gln Leu Leu Lys Gly Asn 
                85                  90                  95      


Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr 
            100                 105                 110         


Cys Cys Ile Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Leu 
        115                 120                 125             


Lys Val Asn Ala Pro Tyr Arg Lys Ile Asn Gln Arg Ile Ser Val Asp 
    130                 135                 140                 


Pro Ala Thr Ser Glu His Glu Leu Ile Cys Gln Ala Glu Gly Tyr Pro 
145                 150                 155                 160 


Glu Ala Glu Val Ile Trp Thr Asn Ser Asp His Gln Pro Val Ser Gly 
                165                 170                 175     


Lys Arg Ser Val Thr Thr Ser Arg Thr Glu Gly Met Leu Leu Asn Val 
            180                 185                 190         


Thr Ser Ser Leu Arg Val Asn Ala Thr Ala Asn Asp Val Phe Tyr Cys 
        195                 200                 205             


Thr Phe Trp Arg Ser Gln Pro Gly Gln Asn His Thr Ala Glu Leu Ile 
    210                 215                 220                 


Ile Pro Glu Leu Pro Ala Thr His Pro Pro Gln Asn Arg Thr His Trp 
225                 230                 235                 240 


Val Leu Leu Gly Ser Ile Leu Leu Phe Leu Ile Val Val Ser Thr Val 
                245                 250                 255     


Leu Leu Phe Leu Arg Lys Gln Val Arg Met Leu Asp Val Glu Lys Cys 
            260                 265                 270         


Gly Val Glu Asp Thr Ser Ser Lys Asn Arg Asn Asp Thr Gln Phe Glu 
        275                 280                 285             


Glu Thr 
    290 


